• Provide your information above to be contacted by a DermaSensor rep.
  • This field is for validation purposes and should be left unchanged.

DermaSensor™ is the New Standard of Skin Cancer Care

Rapid Recording

Rapid Recording

Evaluation process requires less than 30 seconds per skin lesion from start to finish

Easy to Use

Easy to Use

Wireless, ergonomic design makes the device intuitive to learn and easy to use

Optical Spectroscopy

Optical Spectroscopy

Light-emitting tip non-invasively touches the lesion, receiving and analyzing data from below the skin at cellular and subcellular levels

Risk Assessment

Risk Assessment

Provides an instant “Higher Risk” or “Lower Risk” result using DermaSensor’s proprietary algorithm

Simple Design.
Effortless Application

  • Intuitive on-screen user interface guides you step-by-step through the evaluation
  • Activate a recording using either the touch-screen interface or conveniently positioned side buttons

DermaSensor is not a camera or dermatoscope. DermaSensor uses pulses of light and elastic scattering spectroscopy to assess a lesion’s cellular and sub-cellular structures.

Ready to learn more?

How It Works

Lesion Identification

1. Lesion Detection

Identify the lesion of concern on your patient, and simply pick up the wireless, non-invasive device.

DermaSensor Scan

2. DermaSensor Scan

Gently touch the small device tip to the lesion, taking instant spectroscopic recordings at different positions of the lesion.

Photo Scattering

3. Photon Scattering

Light scatters from particles in the cells of the skin tissue back to DermaSensor's spectral sensor.

Algorithmic Analysis

4. Algorithmic Analysis

Our proprietary algorithm analyzes the photons and provides an immediate "Higher Risk" or "Lower Risk" result.

Safety and Efficacy Results for DERM-ASSESS II Prospective, Multi-Centre Study

Study reported no adverse events as well as no significant difference between DermaSensor's and dermatologists' sensitivity and specificity

DermaSensor's sensitivity for melanoma was 100.0%* while the study dermatologists' was 90.9%. For BCC and SCC, also known as Non-Melanoma Skin Cancer (NMSC), DermaSensor's sensitivity was 93.3% and the dermatologists'. was 98.3%

DermaSensor Device and Dermatologist Sensitivity For Skin Cancers
Overall Sensitivity
Melanoma Sensitivity
NMSC Sensitivity
DermaSensor Device
Dermatologist In-Person Assessment
Scroll to Top